

February 3, 2006

AnGes MG, Inc.

**Termination of Joint Development with Seikagaku Corporation**

Seikagaku Corporation and AnGes MG, Inc. have been collaborating in the development of an intra-articular injection formulation using NFκB decoy oligodeoxynucleotide (NFκB decoy oligo). AnGes MG has announced that both companies have agreed to terminate such joint development activities.

The purpose of this joint development was, to optimize an effective intra-articular injection formulation, using NFκB decoy oligo for treating rheumatoid arthritis and osteoarthritis.

Seikagaku Corporation decided to terminate its participation to the joint development activities because of economical reasons associated with the prolonged development period. AnGes MG will continue development of a novel intra-articular injectable formulation with NFκB decoy oligo for rheumatoid arthritis and osteoarthritis.